Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergen Immunotherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    149 result(s) found for: Allergen Immunotherapy. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2009-016815-39 Sponsor Protocol Number: il-ASIT1 Start Date*: 2010-01-15
    Sponsor Name:Allergy Unit Department of Oto-rhino-Laryngology Lund/Malmö University Hospital
    Full Title: Is Intralymphatic Allergen Immunotherapy effective and safe: A human randomized clinical trial
    Medical condition: Seasonal Allergic rhinitis due to pollen from grass and betula verrucosa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-007096-32 Sponsor Protocol Number: PREV1234 Start Date*: 2009-01-07
    Sponsor Name:Medizinische Universität Wien, Univ. Kinderklinik
    Full Title: Prevention od new sensitization by sublingual immunotherapy in children 2-4 years of age with allergic mono-sensitization
    Medical condition: Children (2-4years of age) from atopy prone families with an allergic sensitization as defined by positive skin prick test or positive allergen-specific IgE to grass pollen or house dust mite aller...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000487-28 Sponsor Protocol Number: VO72.12 Start Date*: 2013-08-20
    Sponsor Name:STALLERGENES SA
    Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
    Medical condition: house dust mite-associated allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000617-20 Sponsor Protocol Number: SMART_2 Start Date*: 2013-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlle...
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004194-12 Sponsor Protocol Number: CS-BM32-nasal-001 Start Date*: 2012-10-23
    Sponsor Name:Medizinische Universität Wien, HNO Klinik
    Full Title: The effect of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy, on immunoglobulin levels in nasal secretions of patients suffering from seasonal allergic rhinitis
    Medical condition: Grass pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023536-16 Sponsor Protocol Number: ITN043AD Start Date*: 2011-02-25
    Sponsor Name:University of California, San Francisco, Immune Tolerance Network
    Full Title: A Randomised, Double-blind, Single-centre, Placebo controlled Study of Sublingual Immunotherapy and Subcutaneous Immunotherapy in Adults with Seasonal Allergic Rhinitis (ITN043AD)
    Medical condition: Grass-pollen induced rhinoconjunctivitis (hay fever).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003732-72 Sponsor Protocol Number: 13IC0847 Start Date*: 2013-10-14
    Sponsor Name:Imperial College London
    Full Title: Randomised placebo-controlled study of grass pollen allergen immunotherapy tablet (AIT) for seasonal rhinitis: time course of nasal, cutaneous and immunological outcomes
    Medical condition: Grass-pollen induced rhinoconjunctivitis (hay fever).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000820-27 Sponsor Protocol Number: MM09-SIT-013 Start Date*: 2016-02-16
    Sponsor Name:Inmunotek, S.L.
    Full Title: Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against a mixture of Dermatophagoides pteronyssinus and Derma...
    Medical condition: Mites allergy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001454-77 Sponsor Protocol Number: VO57.07 Start Date*: 2007-09-12
    Sponsor Name:Stallergenes S.A
    Full Title: A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets o...
    Medical condition: House dust mite allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) DE (Completed) ES (Completed) NL (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002844-18 Sponsor Protocol Number: 04071962 Start Date*: 2017-01-16
    Sponsor Name:Medical University of Vienna, Dpt. of Pediatrics
    Full Title: Preventive sublingual immunotherapy for house dust mite sensitized preschool children
    Medical condition: Patients; children at age 4 years with house dust mite IgE sensitization without allergic disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002533-42 Sponsor Protocol Number: ARC002 Start Date*: 2021-12-07
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001259-63 Sponsor Protocol Number: Pollenvaccine2014-01-15 Start Date*: 2016-03-09
    Sponsor Name:Department of Clinical Science, Intervention and Technology, Karolinska Institute
    Full Title: Intralymphatic immunotherapy in increasing doses up to 10 000 SQ-U -a human randomized clinical trial
    Medical condition: Patients with severe to moderate Allegic rhinitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011999-30 Sponsor Protocol Number: VO64.08 Start Date*: 2009-09-16
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets on...
    Medical condition: House Dust Mite Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) DE (Prematurely Ended) FR (Completed) DK (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000492-32 Sponsor Protocol Number: T16/2013 Start Date*: 2013-07-10
    Sponsor Name:Turku University Hospital
    Full Title: T cell and interferon expression in tonsils after sublingual immunotherapy and/or nasal live attenuated influenza vaccine
    Medical condition: We investigate the effects of allergen and virus on patients with recurrent tonsillitis or tonsillar hypertrphy.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001521-19 Sponsor Protocol Number: MS04062004 Start Date*: 2004-09-01
    Sponsor Name:SEVAPHARMA a.s.
    Full Title: An open clinical trial on teh efficacy of H-AL pollens (Grass mixture I) administered orally and sublingually in patients with indicated allergen immunotherapy (AIT) with Type I allergy mediated by...
    Medical condition: Type I allergy to pollens mediated by IgE antibodies
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001029-84 Sponsor Protocol Number: AL0702rB Start Date*: 2007-08-30
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoall...
    Medical condition: ICD classification code: J45.0 and J30.1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-002944-18 Sponsor Protocol Number: BIA-HDMP-201 Start Date*: 2016-11-14
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC R...
    Medical condition: The disease under study is allergic rhinoconjunctivitis secondary to sensitization to DPT and DF. Included in the study are patients diagnosed with that disease who also have associated mild asthma...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000326-58 Sponsor Protocol Number: ARC009 Start Date*: 2018-09-27
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real-World, Open-Label, Quality of Life Study
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015679-28 Sponsor Protocol Number: RHM CHI0499 Start Date*: 2010-09-29
    Sponsor Name:Southampton University Hospitals Trust
    Full Title: PRIMARY PREVENTION OF ATOPY AND ASTHMA WITH ALLERGEN SUBLINGUAL IMMUNOTHERAPY
    Medical condition: Development of atopy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019857 Hereditary allergy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002087-47 Sponsor Protocol Number: ARC001 Start Date*: 2021-12-07
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT)
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA